Sarepta Therapeutics Inc (SRPT) : Perceptive Advisors reduced its stake in Sarepta Therapeutics Inc by 1.72% during the most recent quarter end. The investment management company now holds a total of 3,767,316 shares of Sarepta Therapeutics Inc which is valued at $147,377,402 after selling 65,812 shares in Sarepta Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Sarepta Therapeutics Inc makes up approximately 9.55% of Perceptive Advisors’s portfolio.
Other Hedge Funds, Including , Aqr Capital Management added SRPT to its portfolio by purchasing 4,981 company shares during the most recent quarter which is valued at $194,857.Benchmark Capital Advisors reduced its stake in SRPT by selling 57,150 shares or 91.95% in the most recent quarter. The Hedge Fund company now holds 5,000 shares of SRPT which is valued at $205,000. Sarepta Therapeutics Inc makes up approx 0.16% of Benchmark Capital Advisors’s portfolio.Blackrock Advisors boosted its stake in SRPT in the latest quarter, The investment management firm added 697,122 additional shares and now holds a total of 839,928 shares of Sarepta Therapeutics Inc which is valued at $32,639,602. Sarepta Therapeutics Inc makes up approx 0.04% of Blackrock Advisors’s portfolio.Teacher Retirement System Of Texas reduced its stake in SRPT by selling 1,322 shares or 21.91% in the most recent quarter. The Hedge Fund company now holds 4,712 shares of SRPT which is valued at $184,758. Td Asset Management Inc added SRPT to its portfolio by purchasing 20,800 company shares during the most recent quarter which is valued at $777,712.
Sarepta Therapeutics Inc opened for trading at $38.86 and hit $39.362 on the upside on Monday, eventually ending the session at $38.74, with a gain of 0.03% or 0.01 points. The heightened volatility saw the trading volume jump to 20,04,759 shares. Company has a market cap of $2,115 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.33 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $-1.28.During the same quarter in the previous year, the company posted $-1.11 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Shares were Reiterated by RBC Capital Mkts on Oct 28, 2016 to “Outperform” and Lowered the Price Target to $ 106 from a previous price target of $108 .Morgan Stanley Initiated Sarepta Therapeutics Inc on Oct 27, 2016 to “Equal-Weight”, Price Target of the shares are set at $53.Credit Suisse Initiated Sarepta Therapeutics Inc on Oct 18, 2016 to “Outperform”, Price Target of the shares are set at $68.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.